161 related articles for article (PubMed ID: 27432071)
1. Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents.
Samson SL; Garber AJ
Best Pract Res Clin Endocrinol Metab; 2016 Jun; 30(3):357-71. PubMed ID: 27432071
[TBL] [Abstract][Full Text] [Related]
2. [Is type-2 diabetes mellitus preventable?].
Jermendy G
Orv Hetil; 2003 Sep; 144(39):1909-17. PubMed ID: 14598569
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological interventions in the prevention of type 2 diabetes.
Henness S
Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):166-9. PubMed ID: 17940436
[TBL] [Abstract][Full Text] [Related]
4. Changes in glucose metabolism in people with different glucose metabolism disorders at baseline: follow-up results of a Finnish national diabetes prevention programme.
Rautio N; Jokelainen J; Oksa H; Saaristo T; Peltonen M; Puolijoki H; Tuomilehto J; Vanhala M; Moilanen L; Uusitupa M; Keinänen-Kiukaanniemi S
Diabet Med; 2015 Dec; 32(12):1611-6. PubMed ID: 25864699
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance.
Smith-Marsh D
Drugs Today (Barc); 2013 Aug; 49(8):499-507. PubMed ID: 23977667
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
7. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
Petersen JL; McGuire DK
Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
[TBL] [Abstract][Full Text] [Related]
8. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
Kusakabe T; Ebihara K; Sakai T; Miyamoto L; Aotani D; Yamamoto Y; Yamamoto-Kataoka S; Aizawa-Abe M; Fujikura J; Hosoda K; Nakao K
Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E924-31. PubMed ID: 22275759
[TBL] [Abstract][Full Text] [Related]
9. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.
Scheen AJ; Van Gaal LF
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):911-22. PubMed ID: 24731666
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic implications of diabetes in cardiovascular disease.
Cherian B; Meka N; Katragadda S; Arora R
Am J Ther; 2009; 16(6):e51-9. PubMed ID: 19940606
[TBL] [Abstract][Full Text] [Related]
11. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen AJ; Ernest P
Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
[TBL] [Abstract][Full Text] [Related]
12. Interrupting the natural history of diabetes mellitus: lifestyle, pharmacological and surgical strategies targeting disease progression.
Khavandi K; Brownrigg J; Hankir M; Sood H; Younis N; Worth J; Greenstein A; Soran H; Wierzbicki A; Goldsmith DJ
Curr Vasc Pharmacol; 2014 Jan; 12(1):155-67. PubMed ID: 22272898
[TBL] [Abstract][Full Text] [Related]
13. Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes.
Lau DC; Teoh H
Can J Diabetes; 2015 Dec; 39 Suppl 5():S134-41. PubMed ID: 26654857
[TBL] [Abstract][Full Text] [Related]
14. [Prevention of type 2 diabetes--an overview].
Qvigstad E
Tidsskr Nor Laegeforen; 2004 Dec; 124(23):3047-50. PubMed ID: 15586184
[TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetes and obesity in adults.
Whitmore C
Br J Nurs; 2010 Jul 22-Aug 11; 19(14):880, 882-6. PubMed ID: 20647979
[TBL] [Abstract][Full Text] [Related]
16. Can type 2 diabetes mellitus be considered preventable?
Jermendy G
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S73-81. PubMed ID: 15955380
[TBL] [Abstract][Full Text] [Related]
17. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents.
Saxon DR; Rasouli N; Eckel RH
Drugs; 2018 Feb; 78(2):203-214. PubMed ID: 29305768
[TBL] [Abstract][Full Text] [Related]
19. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
20. Metformin: new understandings, new uses.
Hundal RS; Inzucchi SE
Drugs; 2003; 63(18):1879-94. PubMed ID: 12930161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
